Recent advances in T-cell immunotherapy for haematological malignancies.
Recent advances in T-cell immunotherapy for haematological malignancies.
复制标题
DOI：
10.1111/bjh.14470
复制
发表时间：
2017-03
影响因子：
6.5
通讯作者：
Heslop HE
中科院分区：
文献类型：
--
作者：
Rouce RH;Sharma S;Huynh M;Heslop HE
体外发现为通过Typerive T细胞免疫疗法中的基准对床层翻译铺平了道路，从而在各种血液学恶性肿瘤中产生了显着的临床反应。通过基因修饰以表达CD19汽车的经过转移的T细胞表现出了很大的希望，尽管有关如何优化T细胞疗法以确保安全和功效的许多未解决的问题。同样，尽管其天然受体识别病毒或肿瘤抗原的T细胞产生了令人鼓舞的临床反应。磨练制造过程将增加T细胞产品的可用性，而结合T细胞疗法的能力可以提高完整的响应率。最后，控制这些疗法的创新机制可以改善安全概况，而基因组编辑则提供了调节T细胞功能的前景。这篇综述将重点介绍T细胞免疫疗法的最新进展，强调临床和临床前的进步，并探索未来的情况。
In vitro discoveries have paved the way for bench-to-bedside translation in adoptive T cell immunotherapy, resulting in remarkable clinical responses in a variety of haematological malignancies. Adoptively transferred T cells genetically modified to express CD19 CARs have shown great promise, although many unanswered questions regarding how to optimize T-cell therapies for both safety and efficacy remain. Similarly, T cells that recognize viral or tumour antigens though their native receptors have produced encouraging clinical responses. Honing manufacturing processes will increase the availability of T-cell products, while combining T-cell therapies has the ability to increase complete response rates. Lastly, innovative mechanisms to control these therapies may improve safety profiles while genome editing offers the prospect of modulating T-cell function. This review will focus on recent advances in T-cell immunotherapy, highlighting both clinical and pre-clinical advances, as well as exploring what the future holds.